Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
NCT03910543Phase 1Completed
- Sponsor
- Yale University
- Start
- Apr 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tofacitinib in cutaneous sarcoidosis and granuloma annulare (GA) (2 arms), sponsored by Yale University. Primary endpoints: Cutaneous Sarcoidosis Activity and Morphology Instrument at 12 months, Granuloma Activity Scoring Index at 6 months and 1 more. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
cutaneous sarcoidosisgranuloma annulare (GA)
Beyond the preview
Go deeper on NCT03910543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910543.